Is personalized medicine a panacea for health management? Some thoughts on its desirability

Autor: Antoñanzas Villar, Fernando JesúsJuárez Castelló, Carmelo ArturoRodríguez Ibeas, Roberto

Tipo de documento: Artículo de revista

Revista: European Journal of Health Economics. ISSN: 1618-7598. Año: 2015. Número: 5. Volumen: 16. Páginas: 455-457.

Texto completo open access 

JCR (datos correspondientes al año 2014):
Edición:
Social Sciences  Área: ECONOMICS  Quartil: Q1  Lugar área: 53/333  F. impacto: 1,774 
Edición:
Social Sciences  Área: HEALTH POLICY & SERVICES  Quartil: Q2  Lugar área: 29/71  F. impacto: 1,774 

SCIMAGO (datos correspondientes al año 2014):
SJR:
,768  SNIP: 1,05 

CARHUS Plus+: A

CIRC: GRUPO A - EXCELENCIA

Referencias:

  • Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., Alagoz, O., Siebert, U., Concepts of ‘‘Personalization’’ in personalized medicine: implications for economic evaluation (2014) PharmacoEconomics, , PID: 24574059
  • Hatz, M.H.M., Schremser, K., Rogowski, W.H., Is individualized medicine more cost-effective? A systematic review (2014) PharmacoEconomics, 32, pp. 443-455. , PID: 24574059
  • Trusheim, M.R., Berndt, E.R., Douglas, F.L., Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007) Nat Rev Drug Discov, 6, p. 28793
  • Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M., Genetic testing in the European Union: does economic evaluation matter? (2012) Eur J Health Econ, 12 (5), pp. 651-662
  • Antoñanzas, F., Juárez-Castelló, C.A., Rodríguez-Ibeas, R., Some economics on personalized and predictive medicine (2014) Eur J Health Econ
  • http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002051.jsp&
  • mid=WC0b01ac058004d5c1, European Medicines Agency (EMA): EMA recommends approval of new treatment for platinum-resistant ovarian cancer together with companion diagnostic. accessed 28 November 2014